1
|
Liang Y, Zhao B, Shen Y, Peng M, Qiao L, Liu J, Pan Y, Yang K, Liu W. Elucidating the Role of circTIAM1 in Guangling Large-Tailed Sheep Adipocyte Proliferation and Differentiation via the miR-485-3p/ PLCB1 Pathway. Int J Mol Sci 2024; 25:4588. [PMID: 38731807 PMCID: PMC11083075 DOI: 10.3390/ijms25094588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 04/10/2024] [Accepted: 04/20/2024] [Indexed: 05/13/2024] Open
Abstract
Fat tissue-a vital energy storage organ-is intricately regulated by various factors, including circular RNA, which plays a significant role in modulating fat development and lipid metabolism. Therefore, this study aims to clarify the regulatory mechanism of sheep adipocyte proliferation and differentiation by investigating the involvement of circTIAM1, miR-485-3p, and its target gene PLCB1. Through previous sequencing data, circTIAM1 was identified in sheep adipocytes, with its circularization mechanism elucidated, confirming its cytoplasmic localization. Experimental evidence from RNase R treatment and transcription inhibitors highlighted that circTIAM1 is more stable than linear RNA. Additionally, circTIAM1 promoted sheep adipocyte proliferation and differentiation. Furthermore, bioinformatic analysis demonstrated a robust interaction between miR-485-3p and circTIAM1. Further experiments revealed that miR-485-3p inhibits fat cell proliferation and differentiation by inhibiting PLCB1, with circTIAM1 alleviating the inhibitory effect via competitive binding. In summary, our findings elucidate the mechanism through which circTIAM1 regulates Guangling Large-Tailed sheep adipocyte proliferation and differentiation via the miR-485-3p-PLCB1 pathway, offering a novel perspective for further exploring fat metabolism regulation.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Wenzhong Liu
- College of Animal Science, Shanxi Agricultural University, Jinzhong 030801, China
| |
Collapse
|
2
|
Song TJ, Ke J, Chen F, Zhang JY, Zhang C, Chen HY. Effect of SNHG11/miR-7-5p/ PLCB1 Axis on Acute Pancreatitis through Inhibiting p38MAPK Pathway. Cells 2022; 12:cells12010065. [PMID: 36611865 PMCID: PMC9818913 DOI: 10.3390/cells12010065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 12/09/2022] [Accepted: 12/17/2022] [Indexed: 12/28/2022] Open
Abstract
Acute pancreatitis (AP) is an inflammatory disease of the pancreas. A growing number of studies have shown that long noncoding RNAs (lncRNAs) play an important role in AP progression. Here, we aimed to elucidate the role of Small Nucleolar RNA Host Gene 11(SNHG11) and its underlying molecular mechanisms behind AP progression. The in vivo and in vitro AP cell models were established by retrograde injection of sodium taurocholate and caerulein stimulation into AR42J cells and HPDE6-C7 cells, respectively. A bioinformatics website predicted the relationship between SNHG11, miR-7-5p, and Phospholipase C Beta 1(PLCB1) and validated it with a dual-luciferase reporter assay and an RNA immunoprecipitation (RIP) assay. AR42J cells and HPDE6-C7 cells were transfected with an overexpression of plasmids or shRNA to investigate the effects of the SNHG11/miR-7-5p/PLCB1 axis on cell proliferation and apoptosis, inflammatory cytokine secretion, and acute pancreatitis. Low expression of SNHG11 and PLCB1 and high expression of miR-7-5p were observed in AP pancreatic tissue and AP cell models. SNHG11 overexpression inhibited apoptosis and inflammatory responses induced by caerulein. Simultaneously, we discovered that SNHG11 regulates PLCB1 expression by sponging miR-7-5p. PLCB1 overexpression abrogated inflammatory damage exacerbated by miR-7-5p enrichment. In addition, the SNHG11/miR-7-5p/PLCB1 axis could be involved in caerulein-induced inflammatory injury by participating in the p38MAPK signaling pathway. The overexpressed SNHG11/miR-7-5p/PLCB1 axis can inhibit AP progression by participating in the p38MAPK signaling pathway, thereby providing a potential therapeutic target and therapeutic direction for AP therapy.
Collapse
Affiliation(s)
- Tian-Jiao Song
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, China
- Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou 350001, China
| | - Jun Ke
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, China
- Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou 350001, China
| | - Feng Chen
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, China
- Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou 350001, China
- Correspondence:
| | - Jiu-Yun Zhang
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, China
- Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou 350001, China
| | - Chun Zhang
- Department of Hepatobiliary and Pancreatic Surgery, Mindong Hospital, Ningde, Fujian Medical University, No. 89, Heshan Road, Fuan 355000, China
| | - Hong-Yi Chen
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou 350001, China
- Department of Emergency, Fujian Provincial Hospital, Fuzhou 350001, China
- Fujian Provincial Key Laboratory of Emergency Medicine, Fujian Provincial Institute of Emergency Medicine, Fujian Emergency Medical Center, Fuzhou 350001, China
| |
Collapse
|
3
|
Zhang D, Zhang Y, Zhang X, Zhai H, Sun X, Li Y. Circ_0091579 Serves as a Tumor-Promoting Factor in Hepatocellular Carcinoma Through miR-1225-5p/ PLCB1 Axis. Dig Dis Sci 2022; 67:585-597. [PMID: 33559088 DOI: 10.1007/s10620-021-06861-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 01/18/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is a dreadful threaten to human health worldwide. Many circular RNAs were reported to influence the malignant development of HCC. The aim of this study was to elucidate the role of circ_0091579 in HCC progression and the molecular fundamentation. METHODS Expression of circ_0091579, microRNA-1225-5p (miR-1225-5p), and phospholipase C, β1 (PLCB1) was examined by quantitative reverse transcription-polymerase chain reaction or Western blotting. Cell viability, clonogenicity capacity, and apoptosis were determined via Cell Counting Kit-8 assay, colony formation assay, and flow cytometry, respectively. Transwell assay was employed to detect cell migration and invasion. Target relationship between miR-1225-5p and circ_0091579 or PLCB1 was demonstrated by dual-luciferase reporter assay. Moreover, role of circ_0091579 in vivo was assessed by Xenograft model assay. RESULTS Expression of circ_0091579 and PLCB1 was increased, while miR-1225-5p expression was decreased in HCC tissues and cells. Circ_0091579 or PLCB1 depletion had inhibitory effects on HCC cell proliferation and metastasis. Circ_0091579 sponged miR-1225-5p to upregulate PLCB1 expression in HCC cells. Silencing of miR-1225-5p contributed to HCC progression, which was mitigated by PLCB1 depletion. Circ_0091579 deficiency could suppress HCC tumor growth in vivo. CONCLUSION Circ_0091579 knockdown repressed HCC progression and tumorigenesis by regulating miR-1225-5p/PLCB1 axis, affording a novel molecular basis for HCC development.
Collapse
Affiliation(s)
- Di Zhang
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi'an, 710004, Shaanxi, China
| | - Yu Zhang
- Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
| | - Xiwu Zhang
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi'an, 710004, Shaanxi, China
| | - Hongjun Zhai
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi'an, 710004, Shaanxi, China
| | - Xiaoli Sun
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi'an, 710004, Shaanxi, China
| | - Yiming Li
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi'an, 710004, Shaanxi, China.
| |
Collapse
|
4
|
Ratti S, Evangelisti C, Mongiorgi S, De Stefano A, Fazio A, Bonomini F, Follo MY, Faenza I, Manzoli L, Sheth B, Vidalle MC, Kimber ST, Divecha N, Cocco L, Fiume R. "Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia". Front Oncol 2021; 11:678824. [PMID: 34109125 PMCID: PMC8181149 DOI: 10.3389/fonc.2021.678824] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 05/04/2021] [Indexed: 12/12/2022] Open
Abstract
Polyphosphoinositides (PPIns) and their modulating enzymes are involved in regulating many important cellular functions including proliferation, differentiation or gene expression, and their deregulation is involved in human diseases such as metabolic syndromes, neurodegenerative disorders and cancer, including Acute Myeloid Leukemia (AML). Given that PPIns regulating enzymes are highly druggable targets, several studies have recently highlighted the potential of targeting them in AML. For instance many inhibitors targeting the PI3K pathway are in various stages of clinical development and more recently other novel enzymes such as PIP4K2A have been implicated as AML targets. PPIns have distinct subcellular organelle profiles, in part driven by the specific localisation of enzymes that metabolise them. In particular, in the nucleus, PPIns are regulated in response to various extracellular and intracellular pathways and interact with specific nuclear proteins to control epigenetic cell state. While AML does not normally manifest with as many mutations as other cancers, it does appear in large part to be a disease of dysregulation of epigenetic signalling and many novel therapeutics are aimed at reprogramming AML cells toward a differentiated cell state or to one that is responsive to alternative successful but limited AML therapies such as ATRA. Here, we propose that by combining bioinformatic analysis with inhibition of PPIns pathways, especially within the nucleus, we might discover new combination therapies aimed at reprogramming transcriptional output to attenuate uncontrolled AML cell growth. Furthermore, we outline how different part of a PPIns signalling unit might be targeted to control selective outputs that might engender more specific and therefore less toxic inhibitory outcomes.
Collapse
Affiliation(s)
- Stefano Ratti
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Camilla Evangelisti
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Sara Mongiorgi
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Alessia De Stefano
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Antonietta Fazio
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Francesca Bonomini
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Matilde Y Follo
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Irene Faenza
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Lucia Manzoli
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Bhavwanti Sheth
- Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom
| | - Magdalena C Vidalle
- Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom
| | - Scott T Kimber
- Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom
| | - Nullin Divecha
- Inositide Laboratory, School of Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, United Kingdom
| | - Lucio Cocco
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| | - Roberta Fiume
- Cellular Signalling Laboratory, Department of Biomedical Sciences (DIBINEM), University of Bologna, Bologna, Italy
| |
Collapse
|
5
|
Ha SD, Lewin N, Li SSC, Kim SO. HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells. Cells 2021; 10:1101. [PMID: 34064422 DOI: 10.3390/cells10051101] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 04/29/2021] [Accepted: 04/30/2021] [Indexed: 12/13/2022] Open
Abstract
Inhibition of the RAF-MEK1/2-ERK signaling pathway is an ideal strategy for treating cancers with NRAS or BRAF mutations. However, the development of resistance due to incomplete inhibition of the pathway and activation of compensatory cell proliferation pathways is a major impediment of the targeted therapy. The anthrax lethal toxin (LT), which cleaves and inactivates MEKs, is a modifiable biomolecule that can be delivered selectively to tumor cells and potently kills various tumor cells. However, resistance to LT and the mechanism involved are yet to be explored. Here, we show that LT, through inhibiting MEK1/2-ERK activation, inhibits the proliferation of cancer cells with NRAS/BRAF mutations. Among them, the human colorectal tumor HT-29 and murine melanoma B16-BL6 cells developed resistance to LT in 2 to 3 days of treatment. These resistant cells activated AKT through a histone deacetylase (HDAC) 8-dependent pathway. Using an Affymetrix microarray, followed by qPCR validation, we identified that the differential expression of the phospholipase C-β1 (PLCB1) and squamous cell carcinoma-1 (DESC1) played an important role in HDAC8-mediated AKT activation and resistance to MEK1/2-ERK inhibition. By using inhibitors, small interference RNAs and/or expression vectors, we found that the inhibition of HDAC8 suppressed PLCB1 expression and induced DESC1 expression in the resistant cells, which led to the inhibition of AKT and re-sensitization to LT and MEK1/2 inhibition. These results suggest that targeting PLCB1 and DESC1 is a novel strategy for inhibiting the resistance to MEK1/2 inhibition.
Collapse
|
6
|
Srivastava S, Srikanth K, Won S, Son JH, Park JE, Park W, Chai HH, Lim D. Haplotype-Based Genome-Wide Association Study and Identification of Candidate Genes Associated with Carcass Traits in Hanwoo Cattle. Genes (Basel) 2020; 11:E551. [PMID: 32423003 DOI: 10.3390/genes11050551] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 04/30/2020] [Accepted: 05/05/2020] [Indexed: 12/20/2022] Open
Abstract
Hanwoo, is the most popular native beef cattle in South Korea. Due to its extensive popularity, research is ongoing to enhance its carcass quality and marbling traits. In this study we conducted a haplotype-based genome-wide association study (GWAS) by constructing haplotype blocks by three methods: number of single nucleotide polymorphisms (SNPs) in a haplotype block (nsnp), length of genomic region in kb (Len) and linkage disequilibrium (LD). Significant haplotype blocks and genes associated with them were identified for carcass traits such as BFT (back fat thickness), EMA (eye Muscle area), CWT (carcass weight) and MS (marbling score). Gene-set enrichment analysis and functional annotation of genes in the significantly-associated loci revealed candidate genes, including PLCB1 and PLCB4 present on BTA13, coding for phospholipases, which might be important candidates for increasing fat deposition due to their role in lipid metabolism and adipogenesis. CEL (carboxyl ester lipase), a bile-salt activated lipase, responsible for lipid catabolic process was also identified within the significantly-associated haplotype block on BTA11. The results were validated in a different Hanwoo population. The genes and pathways identified in this study may serve as good candidates for improving carcass traits in Hanwoo cattle.
Collapse
|
7
|
Zhao P, Sun S, Zhai Y, Tian Q, Zhou T, Li J. miR-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase C beta 1. Int J Clin Exp Pathol 2019; 12:2941-2950. [PMID: 31934130 PMCID: PMC6949730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 06/25/2019] [Indexed: 06/10/2023]
Abstract
Glioma is a common brain tumor which is highly invasive, responds poorly to therapy, and has a poor prognosis. There is growing evidence that an abnormal expression of many genes is related to glioma and leads to glioma cell growth and metastasis. Phospholipase C beta 1 (PLCB1) plays critical roles in intracellular transduction and regulating signal activation, which are important to tumorigenesis. Therefore, it could bind to miRNA as a target gene. The purpose of our study was to confirm that PLCB1 plays a critical role in suppressing glioma progression. We found that the expression of miR-423-5p was reduced, but the expression of PLCB1 was increased, in glioma tissues and cells. To explore whether miR-423-5p affects PLCB1, a bioinformatics approach suggested that miR-423-5p can directly target PLCB1. Moreover, we observed, using luciferase reporter assays, that miR-423-5p could target PLCB1 3'-UTR. Functionally, the overexpression of miR-423-5p could attenuate the proliferation, invasion, and migration and promote the apoptosis of glioma cells. Furthermore, we found that miR-423-5p could enhance p-ERK expression in glioma cells. Taken together, we deduced that miR-423-5p inhibited proliferation and metastasis by targeting PLCB1, and it also promotes apoptosis in glioma cells. These results suggest that miR-423-5p directly targets PLCB1 3'-UTR and could inhibit cell invasion and migration through the ERK-dependent pathway in glioma, and the miR-423-5p/PLCB1 axis may be a potential target for new potential therapeutic strategies to treat glioma.
Collapse
Affiliation(s)
- Peng Zhao
- Department of Clinical Laboratory, Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Shukai Sun
- Department of Clinical Laboratory, Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Yu’e Zhai
- Department of Clinical Laboratory, Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Qingwu Tian
- Department of Clinical Laboratory, Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Tingting Zhou
- Department of Clinical Laboratory, Affiliated Hospital of Qingdao UniversityQingdao, China
| | - Jing Li
- Department of Nephrology, Affiliated Hospital of Qingdao UniversityQingdao, China
| |
Collapse
|
8
|
Fais P, Leopizzi M, Di Maio V, Longo L, Della Rocca C, Tagliaro F, Bortolotti F, Lo Vasco VR. Phosphoinositide-specific phospholipase C in normal human liver and in alcohol abuse. J Cell Biochem 2019; 120:7907-7917. [PMID: 30426534 DOI: 10.1002/jcb.28067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 10/22/2018] [Indexed: 01/24/2023]
Abstract
The phosphoinositide (PI) signal transduction pathway participates in liver metabolism. Abnormal activity or expression of PI-specific phospholipase C (PLC) enzymes has been described in different liver diseases. We resume the role of the PI metabolism in liver and PLC abnormalities in different liver diseases. Moreover, we present the results of PLC analyses in a normal human liver and an alcohol-damaged liver. PLC enzymes and the expression of the corresponding genes in liver biopsies from individuals deceased for complications of the alcoholic liver disease (ALD) at different stages compared with normal controls (deceased individuals with histologically normal livers without alcohol addiction anamnesis) were analyzed by using immunohistochemistry and molecular biology techniques. The expression panel of PLCs was described in normal and alcohol abuse liver. Our observations suggest that the regulation of PLC expression might be due to posttranscriptional events and that alcohol affects the epigenetic control of PLC expression belonging to PI signaling. We also describe the alternate expression of PLCB1 and PLCH1 genes in liver. Our results corroborate literature data suggesting that PLC enzymes are differently expressed in normal versus pathological liver, playing a role in the histopathogenesis of liver tissue damage. The expression and/or localization of selected PLC isoforms is especially affected in alcohol-related liver tissue histopathology. Our present observations confirm that the modulation of protein synthesis plays a role in the regulation of PLC enzymes. We also suggest that this modulation might act at the transcription level. Further studies are required to investigate related epigenetic mechanisms.
Collapse
Affiliation(s)
- Paolo Fais
- Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Bologna, Italy
| | - Martina Leopizzi
- Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino-Sapienza University, Latina, Italy
| | - Valeria Di Maio
- Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino-Sapienza University, Latina, Italy
| | - Lucia Longo
- Department of Sensory Organs, Sapienza University of Rome, Rome, Italy
| | - Carlo Della Rocca
- Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino-Sapienza University, Latina, Italy
| | - Franco Tagliaro
- Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Bologna, Italy.,Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino-Sapienza University, Latina, Italy.,Department of Sensory Organs, Sapienza University of Rome, Rome, Italy.,Department of Diagnostics and Public Health, Unit of Forensic Medicine, University of Verona, Verona, Italy
| | - Federica Bortolotti
- Department of Medical and Surgical Sciences, Unit of Legal Medicine, University of Bologna, Bologna, Italy.,Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino-Sapienza University, Latina, Italy.,Department of Sensory Organs, Sapienza University of Rome, Rome, Italy.,Department of Diagnostics and Public Health, Unit of Forensic Medicine, University of Verona, Verona, Italy
| | | |
Collapse
|
9
|
Affiliation(s)
- Kenneth A Myers
- Research Institute of the McGill University Health Center, Montreal, Quebec, Canada; Division of Child Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
| |
Collapse
|
10
|
Li J, Zhao X, Wang D, He W, Zhang S, Cao W, Huang Y, Wang L, Zhou S, Luo K. Up-regulated expression of phospholipase C, β1 is associated with tumor cell proliferation and poor prognosis in hepatocellular carcinoma. Onco Targets Ther 2016; 9:1697-706. [PMID: 27051304 PMCID: PMC4807949 DOI: 10.2147/ott.s97189] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Phospholipase C, β1 (PLCB1) plays critical roles in intracellular transduction and regulating signal activation which are important to tumorigenesis. However, the mechanism of PLCB1 in hepatocellular carcinoma (HCC) is still unknown. This study aims to investigate whether its expression is associated with the clinicopathological parameters and prognosis of the patients with HCC. Methods Immunohistochemistry on two tissue microarrays containing 141 cases of HCC tissues and adjacent non-tumorous tissues were performed to analyze the correlation between PLCB1 expression and clinicopathological features. Kaplan–Meier analysis and Cox multivariate analysis were performed to determine the PLCB1 expression in HCC prognosis. Furthermore, effects of PLCB1 on proliferation of HCC cells were explored using a colony formation assay and apoptosis assay. Results We identified that PLCB1 expression was significantly higher in tumor tissues than that in adjacent non-tumorous tissues and associated with advanced tumor stage. Kaplan–Meier survival analysis showed that patients with PLCB1-positive tumors had poorer survival than the patients with PLCB1-negative tumors. In multivariate analyses, PLCB1 expression was an independent prognostic factor. Moreover, overexpression of PLCB1 in HCC cells promoted cell proliferation and inhibited apoptosis, while knocking down PLCB1 reduced cell viability in vitro. Further investigation found that activation of ERK signaling might involve in PLCB1-mediated cell growth. Conclusion Our study suggests that PLCB1 promotes the progression of HCC and can be served as an independent prognostic factor and a promising therapeutic target in HCC.
Collapse
Affiliation(s)
- Junxiang Li
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Xuya Zhao
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Dazhi Wang
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Wei He
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Shuai Zhang
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Wei Cao
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Yu Huang
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Ling Wang
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Shi Zhou
- Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| | - Kaijian Luo
- Department of Oncology, GuiZhou Cancer Hospital, Cancer Hospital of Guizhou Medical University, Guiyang, People's Republic of China
| |
Collapse
|
11
|
Vakalopoulos C. The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis. Front Pharmacol 2014; 5:277. [PMID: 25566074 PMCID: PMC4266038 DOI: 10.3389/fphar.2014.00277] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Accepted: 11/27/2014] [Indexed: 11/13/2022] Open
Abstract
With the advent of DSM 5 criticism has generally centered on a lack of biological validity of the diagnostic criteria. Part of the problem in describing a nosology of psychosis is the tacit assumption of multiple genetic causes each with an incremental loading on the clinical picture that fails to differentiate a clear underlying pathophysiology of high impact. The aim of this paper is to consolidate a primary theory of deficient muscarinic signaling underlying key clinical features of schizophrenia and its regulation by several important genetic associations including neuregulin, DISC and dysbindin. Secondary reductions in markers for GABAergic function and changes in the levels of interneuron calcium binding proteins parvalbumin and calbindin can be attributed to dysfunctional muscarinic transduction. A parallel association exists for cytokine production. The convergent pathway hypothesis is likewise used to model dopaminergic and glutamatergic theories of schizophrenia. The negative symptom dimension is correlated with dysfunction of Akt and ERK transduction, a major point of convergence. The present paradigm predicts the importance of a recent finding of a deletion in a copy number variant of PLCB1 and its potential use if replicated, as one of the first testable biological markers differentiating schizophrenia from bipolar disorder and further subtyping of schizophrenia into deficit and non-deficit. Potential limitations of PLCB1 as a prospective marker are also discussed.
Collapse
|
12
|
Klenke S, Rump K, Buschkamp K, Engler A, Peters J, Siffert W, Frey UH. Characterization of the PLCB1 promoter and regulation by early growth response transcription factor EGR-1. Eur J Pharmacol 2014; 742:8-14. [PMID: 25192965 DOI: 10.1016/j.ejphar.2014.08.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 08/21/2014] [Accepted: 08/25/2014] [Indexed: 10/24/2022]
Abstract
The Gαq/-Gα11-PLCβ1 pathway is important for intracellular signalling and associated with pathological conditions, such as cardiac hypertrophy. The GNAQ and GNA11 promoters (encoding for Gαq and Gα11) have already been characterized and are both regulated by the transcription factor early growth response 1 (Egr-1). In contrast, the PLCB1 promoter (encoding for the direct downstream effector PLCβ1) has neither been cloned nor characterized. Therefore, the purpose of this study was to 1) characterize the PLCB1 promoter, and 2) assess its potential regulation by Egr-1. By means of 5'- Rapid Amplification of 5'-cDNA ends analysis in human heart tissue we found an initiation of transcription from multiple starting points, the main transcription starting point being located at nt-235 relative to the translation start point. The PLCB1 promoter was cloned and deletion constructs were generated. Luciferase assays were performed in three different cell lines and regulatory regions were identified between nt-595/nt-313 (Hek293: P=0.013; HASMC: P=0.019; H9c2: P=0.005). In electrophoretic mobility shift assays one specific Egr-1 binding site was identified at nt-451/-419 and PLCB1 promoter activity was increased more than 5-fold (Hek293: P=0.0008) and 1,6- fold (H9c2: P=0.0499) following overexpression of Egr-1. Thus, the PLCB1 promoter was characterized for the first time and a specific interaction with the transcription factor Egr-1 was shown. Our data provide a potential molecular mechanism relating to pathophysiological conditions such as cardiac hypertrophy where activation by Egr-1 of Gαq/Gα11-PLCβ1 plays an important role.
Collapse
Affiliation(s)
- Stefanie Klenke
- Institut für Pharmakogenetik, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany; Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany.
| | - Katharina Rump
- Institut für Pharmakogenetik, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany; Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| | - Kai Buschkamp
- Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| | - Andrea Engler
- Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| | - Jürgen Peters
- Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| | - Winfried Siffert
- Institut für Pharmakogenetik, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| | - Ulrich H Frey
- Klinik für Anästhesiologie & Intensivmedizin, Universität Duisburg-Essen and Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany
| |
Collapse
|